Phosphatidylinositol increases HDL-C levels in humans.
Studies have shown that phosphatidylinositol (PI) can stimulate reverse cholesterol transport by enhancing the flux of cholesterol into HDL and by promoting the transport of high density lipoprotein-cholesterol (HDL-C) to the liver and bile. The goal of this study was to determine the safety and therapeutic value of PI after oral administration to normolipidemic human subjects. We performed a randomized 2 week study in 16 normolipidemic subjects. Subjects received either 2.8 or 5.6 g of PI, with or without food. PI was well tolerated by all subjects. PI significantly affected the levels of HDL-C and triglyceride in the plasma of subjects receiving PI with food. The lower dose showed a 13% increase in HDL-C, whereas the high dose showed an increase of 18% over the 2 week period. Both low- and high-dose groups showed significant increases in plasma apolipoprotein A-I. The high dose of PI also decreased plasma triglycerides by 36% in the fed subjects. These data suggest that after only 2 weeks, PI may have a comparable therapeutic value to niacin, with negligible side effects.
Burgess
Jim W
JW
Liponex, Inc., Ottawa, Ontario, Canada, K2G 3R8.
Neville
Tracey A-M
TA
Rouillard
Patricia
P
Harder
Zdena
Z
Beanlands
Donald S
DS
Sparks
Daniel L
DL
D000328:Adult; D016632:Apolipoprotein A-I / Q000378:metabolism; D001646:Bile / Q000378:metabolism; D002784:Cholesterol / Q000378:metabolism; D008076:Cholesterol, HDL / Q000097:blood*; D015331:Cohort Studies; D005215:Fasting; D005260:Female; D006801:Humans; D008099:Liver / Q000378:metabolism; D008297:Male; D009525:Niacin / Q000494:pharmacology; D010716:Phosphatidylinositols / Q000494:pharmacology*; D013997:Time Factors; D014280:Triglycerides / Q000097:blood / Q000378:metabolism
D016632:Apolipoprotein A-I; D008076:Cholesterol, HDL; D010716:Phosphatidylinositols; D014280:Triglycerides; D009525:Niacin; D002784:Cholesterol